AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Surgical Oncology-Oxford is a prestigious academic journal published by Elsevier Science Ltd, dedicated to advancing the field of surgical oncology. Since its establishment in 1992, the journal has provided a vital platform for disseminating cutting-edge research, clinical advancements, and innovative surgical techniques. With a focus on both surgery and oncology, the journal is ranked in the Q2 category in Surgery and Q3 in Oncology for 2023, reflecting its commitment to quality and impactful contributions. It ranks #107 out of 551 in Medicine_Surgery and #184 out of 404 in Medicine_Oncology as per Scopus metrics, illustrating its significant role in the academic landscape. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that only the highest quality research is published. By examining the latest surgical methodologies and oncological insights, Surgical Oncology-Oxford plays a crucial role in enhancing clinical practice and improving patient outcomes, making it an essential resource for researchers, healthcare professionals, and students aiming to stay at the forefront of the field.

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

Hepatoma Research is a pivotal academic journal dedicated to advancing the field of hepatology and oncology, published by OAE PUBLISHING INC. Launched in 2019, this open-access journal has quickly established itself as a valuable resource for researchers and professionals dedicated to the study of liver cancer and related disorders. With an ISSN of 2394-5079 and E-ISSN 2454-2520, it offers insightful research articles and reviews aimed at enhancing clinical practices and understanding the complexities surrounding hepatoma. The journal is ranked in the Q3 category for both hepatology and oncology as of 2023, reflecting its commitment to quality amidst a competitive landscape. With its Scopus rankings placing it at the 47th percentile in hepatology and the 39th percentile in oncology, Hepatoma Research continues to be a crucial platform for disseminating groundbreaking findings. This journal underscores the importance of collaborative research and encourages submissions that contribute to the global discourse on liver cancer treatment and management.

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

ESMO Open is a premier open-access journal published by Elsevier, dedicated to advancing research in the fields of cancer and oncology. Since its inception in 2016, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals, providing a platform for disseminating high-quality, peer-reviewed research. With an impressive Q1 ranking in both Cancer Research and Oncology based on the 2023 category quartiles, ESMO Open ranks within the top tier of its field, showcasing its commitment to excellence and innovation. The journal’s inclusion in Scopus rankings further emphasizes its significant impact, with remarkable placements in the 88th and 83rd percentiles for Oncology and Cancer Research, respectively. Operating under an open access model, ESMO Open ensures that cutting-edge findings and insights are readily available to the global academic community, fostering collaboration and knowledge-sharing to further enhance the understanding and treatment of cancer.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.